Marker Therapeutics (MRKR) Projected to Release Quarterly Earnings on Thursday

Posted by Brenda Bartman on Aug 11th, 2026

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) is projected to release its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $0.6820 million for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 21, 2026 at 4:00 PM ET.

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%. The business had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.78 million. On average, analysts expect Marker Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Marker Therapeutics Trading Up 2.7%

Shares of NASDAQ:MRKR opened at $1.15 on Tuesday. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $2.46. The firm has a market capitalization of $19.17 million, a P/E ratio of -1.89 and a beta of 1.50. The firm’s 50 day moving average is $1.35 and its two-hundred day moving average is $1.45.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MRKR. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a research report on Wednesday, May 20th. Weiss Ratings lowered Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $10.00.

Get Our Latest Analysis on Marker Therapeutics

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MRKR. Jane Street Group LLC acquired a new stake in Marker Therapeutics in the 4th quarter valued at about $60,000. Geode Capital Management LLC grew its stake in shares of Marker Therapeutics by 35.3% in the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock worth $194,000 after purchasing an additional 34,028 shares during the last quarter. NewEdge Advisors LLC bought a new stake in shares of Marker Therapeutics in the 4th quarter worth approximately $222,000. Renaissance Technologies LLC raised its holdings in shares of Marker Therapeutics by 16.4% in the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after purchasing an additional 17,400 shares in the last quarter. Finally, Osaic Holdings Inc. raised its holdings in shares of Marker Therapeutics by 16.5% in the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares in the last quarter. 22.39% of the stock is owned by institutional investors and hedge funds.

About Marker Therapeutics

(Get Free Report)

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.